Lupin (LUPIN) Fundamentals 2026 — P/E 20.6x, Revenue Analysis | SniperIQ
Lupin (LUPIN) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹1.10 Lakh Crore, trading at ₹2405.80 on the BSE. This SniperIQ fundamentals page covers Lupin's valuation (P/E 20.6x, P/B 4.9x), profitability (net margin 19.1%), revenue (₹27,958 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lupin's market cap?
Lupin (LUPIN) has a market capitalization of approximately ₹1.10 Lakh Crore, trading at ₹2405.80 on the BSE. Market cap moves with the live share price.
What is Lupin's P/E ratio?
Lupin's trailing twelve-month P/E ratio is 20.6x, with a price-to-book (P/B) of 4.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lupin?
Lupin runs a net profit margin of 19.1%, a gross margin of 62.9%, and an operating margin of 32.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lupin generate?
Lupin reported revenue of ₹27,958 Crore for fiscal year 2026, with net income of ₹5,333 Crore and earnings per share (EPS) of 116.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lupin pay a dividend?
Lupin offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Lupin financially healthy?
Lupin carries a debt-to-equity ratio of 0.29x and a current ratio of 1.90x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lupin a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lupin (LUPIN) the key facts are: market cap ₹1.10 Lakh Crore, P/E 20.6x, revenue ₹27,958 Crore, 52-week range 1774-2498.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lupin's full fundamentals live
Get Lupin's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.